AstraZeneca (AZN) Competitors

£138.20 +54.00 (+0.39%)

As of 06:16 AM Eastern

AZN vs. GSK, ITH, SOPH, INDV, and HCM

Should you buy AstraZeneca stock or one of its competitors? MarketBeat compares AstraZeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AstraZeneca include GSK (GSK), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does AstraZeneca compare to GSK?

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

GSK has a beta of 0.298, suggesting that its share price is 70% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.223, suggesting that its share price is 78% less volatile than the broader market.

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.78%	35.78%	9.56%
AstraZeneca	17.19%	22.41%	7.68%

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 6 mentions for AstraZeneca and 3 mentions for GSK. AstraZeneca's average media sentiment score of 0.12 beat GSK's score of 0.11 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AstraZeneca	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.5%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. GSK pays out 46.4% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK presently has a consensus target price of GBX 2,034.29, indicating a potential upside of 7.78%. AstraZeneca has a consensus target price of £153.33, indicating a potential upside of 10.95%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£32.78B	2.30	£2.50B	£142.10	13.28
AstraZeneca	£60.44B	3.55	£8.71B	£664.00	20.81

45.0% of GSK shares are owned by institutional investors. Comparatively, 64.8% of AstraZeneca shares are owned by institutional investors. 0.2% of GSK shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Ithaca Energy?

AstraZeneca (LON:AZN) and Ithaca Energy (LON:ITH) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

AstraZeneca currently has a consensus target price of £153.33, suggesting a potential upside of 10.95%. Ithaca Energy has a consensus target price of GBX 205, suggesting a potential downside of 26.15%. Given AstraZeneca's higher probable upside, research analysts clearly believe AstraZeneca is more favorable than Ithaca Energy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ithaca Energy	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Ithaca Energy pays an annual dividend of GBX 30.31 per share and has a dividend yield of 10.9%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Ithaca Energy pays out -594.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ithaca Energy is clearly the better dividend stock, given its higher yield and lower payout ratio.

AstraZeneca has a beta of 0.223, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Ithaca Energy has a beta of 0.353, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, AstraZeneca had 5 more articles in the media than Ithaca Energy. MarketBeat recorded 6 mentions for AstraZeneca and 1 mentions for Ithaca Energy. Ithaca Energy's average media sentiment score of 1.83 beat AstraZeneca's score of 0.12 indicating that Ithaca Energy is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ithaca Energy	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

AstraZeneca has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.55	£8.71B	£664.00	20.81
Ithaca Energy	£2.95B	1.56	£230.29M	-£5.10	N/A

AstraZeneca has a net margin of 17.19% compared to Ithaca Energy's net margin of -2.85%. AstraZeneca's return on equity of 22.41% beat Ithaca Energy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
Ithaca Energy	-2.85%	-3.13%	0.18%

64.8% of AstraZeneca shares are held by institutional investors. Comparatively, 3.6% of Ithaca Energy shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 0.2% of Ithaca Energy shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

AstraZeneca beats Ithaca Energy on 12 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Sophos Group plc (SOPH.L) (LON:SOPH) and AstraZeneca (LON:AZN) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

AstraZeneca has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sophos Group plc (SOPH.L)	£726.90M	0.00	N/A	£1.70	N/A
AstraZeneca	£60.44B	3.55	£8.71B	£664.00	20.81

AstraZeneca has a consensus target price of £153.33, suggesting a potential upside of 10.95%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Sophos Group plc (SOPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sophos Group plc (SOPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, AstraZeneca had 6 more articles in the media than Sophos Group plc (SOPH.L). MarketBeat recorded 6 mentions for AstraZeneca and 0 mentions for Sophos Group plc (SOPH.L). AstraZeneca's average media sentiment score of 0.12 beat Sophos Group plc (SOPH.L)'s score of 0.00 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Overall Sentiment
Sophos Group plc (SOPH.L)	Neutral
AstraZeneca	Neutral

Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

64.8% of AstraZeneca shares are held by institutional investors. 0.2% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AstraZeneca has a net margin of 17.19% compared to Sophos Group plc (SOPH.L)'s net margin of 0.00%. AstraZeneca's return on equity of 22.41% beat Sophos Group plc (SOPH.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sophos Group plc (SOPH.L)	N/A	N/A	N/A
AstraZeneca	17.19%	22.41%	7.68%

Summary

AstraZeneca beats Sophos Group plc (SOPH.L) on 13 of the 15 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

AstraZeneca (LON:AZN) and Indivior (LON:INDV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.55	£8.71B	£664.00	20.81
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

AstraZeneca presently has a consensus target price of £153.33, suggesting a potential upside of 10.95%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities analysts plainly believe AstraZeneca is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, AstraZeneca had 5 more articles in the media than Indivior. MarketBeat recorded 6 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.30 beat AstraZeneca's score of 0.12 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.3%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca has a beta of 0.223, meaning that its share price is 78% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

64.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AstraZeneca has a net margin of 17.19% compared to Indivior's net margin of 14.30%. AstraZeneca's return on equity of 22.41% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
Indivior	14.30%	-41.70%	2.37%

Summary

AstraZeneca beats Indivior on 14 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to HUTCHMED?

AstraZeneca (LON:AZN) and HUTCHMED (LON:HCM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

AstraZeneca has a beta of 0.223, meaning that its stock price is 78% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.453, meaning that its stock price is 55% less volatile than the broader market.

64.8% of AstraZeneca shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, AstraZeneca had 5 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for AstraZeneca and 1 mentions for HUTCHMED. AstraZeneca's average media sentiment score of 0.12 beat HUTCHMED's score of -1.05 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

HUTCHMED has a net margin of 104.77% compared to AstraZeneca's net margin of 17.19%. HUTCHMED's return on equity of 41.38% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.19%	22.41%	7.68%
HUTCHMED	104.77%	41.38%	-5.90%

AstraZeneca presently has a consensus target price of £153.33, suggesting a potential upside of 10.95%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities research analysts plainly believe AstraZeneca is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AstraZeneca has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£60.44B	3.55	£8.71B	£664.00	20.81
HUTCHMED	£548.51M	3.00	-£52.98M	£53.00	3.62

Summary

AstraZeneca beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	AstraZeneca	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£214.33B	£73.69B	£6.30B	£2.78B
Dividend Yield	1.72%	2.41%	2.79%	6.09%
P/E Ratio	20.81	25.10	21.03	365.94
Price / Sales	3.55	146.63	548.94	88,399.10
Price / Cash	38.89	16.11	42.94	27.89
Price / Book	5.25	3.55	9.84	7.72
Net Income	£8.71B	£3.18B	£3.55B	£5.89B
7 Day Performance	3.80%	-0.98%	-0.52%	0.49%
1 Month Performance	-7.36%	-1.87%	1.21%	2.48%
1 Year Performance	37.90%	24.51%	41.24%	87.19%

AstraZeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN AstraZeneca	3.3113 of 5 stars	£138.20 +0.4%	£153.33 +11.0%	+35.2%	£214.33B	£60.44B	20.81	83,500	Analyst Forecast High Trading Volume
GSK GSK	3.3107 of 5 stars	GBX 1,857 -2.3%	GBX 2,055.71 +10.7%	+38.9%	£74.22B	£32.78B	13.07	70,212
ITH Ithaca Energy	1.1099 of 5 stars	GBX 270.13 +1.2%	GBX 205 -24.1%	+94.9%	£4.46B	£2.95B	N/A	220
SOPH Sophos Group plc (SOPH.L)	N/A	N/A	N/A	N/A	£2.99B	£726.90M	341.41	520
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+46.3%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Competitors

AZN vs. GSK, ITH, SOPH, INDV, and HCM

How does AstraZeneca compare to GSK?

Summary

How does AstraZeneca compare to Ithaca Energy?

Summary

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Summary

How does AstraZeneca compare to Indivior?

Summary

How does AstraZeneca compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Competitors

AZN vs. GSK, ITH, SOPH, INDV, and HCM

How does AstraZeneca compare to GSK?

Which has more volatility & risk, GSK or AZN?

Is GSK or AZN more profitable?

Does the media refer more to GSK or AZN?

Is GSK or AZN a better dividend stock?

Do analysts prefer GSK or AZN?

Which has better earnings & valuation, GSK or AZN?

Do institutionals and insiders believe in GSK or AZN?

Summary

How does AstraZeneca compare to Ithaca Energy?

Do analysts prefer AZN or ITH?

Is AZN or ITH a better dividend stock?

Which has more volatility & risk, AZN or ITH?

Does the media prefer AZN or ITH?

Which has preferable valuation and earnings, AZN or ITH?

Is AZN or ITH more profitable?

Do institutionals and insiders believe in AZN or ITH?

Summary

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

Which has better valuation & earnings, SOPH or AZN?

Do analysts prefer SOPH or AZN?

Does the media refer more to SOPH or AZN?

Is SOPH or AZN a better dividend stock?

Do institutionals & insiders have more ownership in SOPH or AZN?

Is SOPH or AZN more profitable?

Summary

How does AstraZeneca compare to Indivior?

Which has preferable valuation and earnings, AZN or INDV?

Do analysts recommend AZN or INDV?

Does the media refer more to AZN or INDV?

Is AZN or INDV a better dividend stock?

Which has more volatility & risk, AZN or INDV?

Do insiders and institutionals have more ownership in AZN or INDV?

Is AZN or INDV more profitable?

Summary

How does AstraZeneca compare to HUTCHMED?

Which has more volatility & risk, AZN or HCM?

Do institutionals & insiders hold more shares of AZN or HCM?

Does the media refer more to AZN or HCM?

Is AZN or HCM more profitable?

Do analysts recommend AZN or HCM?

Which has preferable earnings & valuation, AZN or HCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools